NCT02626715 - Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 4, 2015

Primary Completion Date

April 12, 2023

Study Completion Date

April 12, 2023

Conditions

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Hematopoietic Stem Cell Transplant (HSCT)

Interventions

DRUG

Reduced-Intensity Conditioning Regimen

Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent

DRUG

Myeloablative Conditioning Regimen

Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent

Trial Locations (1)

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

All Listed Sponsors

lead

Randy Windreich

OTHER